940890-90-4

Basic information

• Product Name: (S)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE
• Synonyms: (S)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE;1-Piperidinecarboxylic acid, 3-[(Methylsulfonyl)oxy]-, 1,1-diMethylethyl ester, (3S)-;1Piperidinecarboxylic acid, 3[(methylsulfonyl)oxy], 1,1dimeth;2-Methyl-2-propanyl (3S)-3-[(methylsulfonyl)oxy]-1-piperidinecarboxylate (S)tertButyl 3(methylsulfonyloxy)piperidine1carboxylate;(S)-1-Boc-3-mesyloxyl-piperidine
• CAS NO: 940890-90-4
• Molecular Formula: C₁₁H₂₁NO₅S
• Molecular Weight: 279.36
• Mol File: 940890-90-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (S)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE(940890-90-4)
• EPA Substance Registry System: (S)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE(940890-90-4)

Safety Data

• Hazardous Substances Data: 940890-90-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE is used as a reactant in the synthesis of non-nucleoside MtbTMPK inhibitors for the development of novel antitubercular drugs. These inhibitors target the Mycobacterium tuberculosis thymidylate kinase enzyme (MtbTMPK), which is essential for the synthesis of thymidine monophosphate, a crucial component of DNA. By inhibiting MtbTMPK, these compounds can effectively combat tuberculosis, a significant global health concern.
In the synthesis process, (S)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE serves as a key intermediate, contributing to the formation of the desired non-nucleoside MtbTMPK inhibitors. Its unique structure allows for the creation of various chemical bonds and interactions that are vital for the biological activity of the final product. As a result, (S)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE is an essential component in the ongoing research and development of new and effective treatments for tuberculosis.

Upstream product

• 14813-01-5 1-benzyl-3-hydroxypiperidine 
• 75-75-2 methanesulfonic acid 
• 143900-44-1 tert-butyl (3S)-3-hydroxypiperidine-1-carboxylate 
• 85275-45-2 N-tert-butoxycarbonyl-3-piperidinol 
• 124-63-0 methanesulfonyl chloride 
• 91599-81-4 (R)-N-benzyl-3-hydroxypiperidine 
• 91599-79-0 (S)-1-N-benzyl-3-hydroxypiperidine 
• 404577-34-0 (R)-3-methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 101469-92-5 (S)-3-hydroxy-pyrrolidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 85838-94-4 N-Boc-1,2,3,6-tetrahydropyridine 
• 946725-84-4 (R)-3-(3-fluoro-phenoxy)-piperidine 
• 946725-84-4 (S)-3-(3-fluoro-phenoxy)-piperidine 
• 902836-20-8 C₁₇H₂₅NO₃ 
• 912761-71-8 (R)-3-m-tolyloxy-piperidine 
• 1061682-78-7 (R)-tert-butyl 3-(dimethylamino)piperidine-1-carboxylate 
• 143900-44-1 tert-butyl (3S)-3-hydroxypiperidine-1-carboxylate 
• 404577-34-0 (R)-3-methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester 
• 85275-46-3 tert-butyl (3R)-3-(p-tolylsulfonyloxy)piperidine-1-carboxylate 
• 143900-43-0 tert-butyl (3R)-3-hydroxypiperidine-1-carboxylate 
• 1412418-47-3 3-(4-phenoxyphenyl)-1-(piperidine-3-yl)-1H-pyrazolo[3,4-d]pyrimidine-4-amine 
• 1642571-07-0 (R)-3-(4-phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidine-4-amine hydrochloride 

Relevant articles and documents

Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs)

Ibrutinib is an inhibitor of Bruton's tyrosine kinase that has been approved for the treatment of patients with chronic lymphocytic leukemia, mantle cell lymphoma and Waldenstrom's macroglobulinemia and is connected with toxicities. To minimize its toxicities, we linked ibrutinib to a cell-targeted, internalizing antibody. To this end, we synthesized a poly-anionic derivate, ibrutinib-Cy3.5, that retains full functionality. This anionic inhibitor is complexed by our anti-CD20-protamine targeting conjugate and free protamine, and thereby spontaneously assembles into an electrostatically stabilized vesicular nanocarrier. The complexation led to an accumulation of the drug driven by the CD20 antigen internalization to the intended cells and an amplification of its pharmacological effectivity. In vivo, we observed a significant enrichment of the drug in xenograft lymphoma tumors in immune-compromised mice and a significantly better response to lower doses compared to the original drug.

BTK Inhibitors and uses thereof

The invention discloses a bruton's tyrosine kinase (BTK) inhibitor and use thereof. Specifically, the invention provides heteroaromatic compounds or stereoisomers, geometrical isomers, tautomers, racemates, nitrogen oxides, hydrates, solvates, metabolites and pharmaceutically acceptable salts or prodrugs thereof, and pharmaceutical compositions containing the heteroaromatic compounds; the invention also discloses use of the heteroaromatic compounds or the pharmaceutical compositions containing the heteroaromatic compounds in preparation of medicines; the medicines can be used for treating autoimmune diseases, inflammatory diseases or proliferative diseases.

ANTITUMOR-EFFECT ENHANCER USING PYRAZOLO[3,4-D]PYRIMIDINE COMPOUND

To provide a method for treating cancer using a pyrazolo[3,4-d]pyrimidine compound or a salt thereof. The present invention provides an antitumor agent comprising a pyrazolo[3,4-d]pyrimidine compound of formula (I) wherein X, Y, Z1, Z2/su

PROCESS FOR THE SYNTHESIS OF STABLE AMORPHOUS IBRUTINIB

Disclosed herein is a new route of synthesis and a new stable amorphous form of ibrutinib. Also disclosed are pharmaceutical compositions, oral dosage forms and the use of the amorphous ibrutinib in the treatment of mantle cell lymphoma or chronic lymphocytic leukemia.

AN IMPROVED PROCESS FOR THE PREPARATION OF IBRUTINIB

The present invention relates to an improved process for the preparation of Ibrutinib with high purity and high yields. The present process is cost effective and feasible in large scale production also. The present process avoids the mitsunobu reagent conditions also. The present Invention also relates to a process for the preparation of Crystalline form A and Crystalline form C of Ibrutinib.

NOVEL SALT OF FUSED PYRIMIDINE COMPOUND AND CRYSTAL THEREOF

Provided is a salt having a high selectivity to BTK and is useful as a drug ingredient for a pharmaceutical product. It has been found that fumarate of Compound A is free of a characteristic of channel hydrate and is stable and excellent in absorptive property, compared to Compound A or other salts thereof.

NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF

To provide a novel compound having a HER2 inhibitory effect and having a cytostatic effect. It is also intended to provide a medicament useful in the prevention and/or treatment of a disease involving HER2, particularly, cancer, on the basis of the HER2 i

Preventive and/or therapeutic agent of immune disease

Provided is a preventive and/or therapeutic agent for immune diseases containing a compound having a BTK inhibitory activity or a salt thereof, as an active ingredient. A preventive and/or therapeutic agent of immune diseases, comprising a compound repres

TYROSINE KINASE INHIBITORS

The present disclosure provides compounds of formula (I) that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ("BTK") inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, au